{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:45:02Z","timestamp":1788306302352,"version":"build-2803163510"},"reference-count":18,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNS"],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:p>Pituitary tumors causing acromegaly are usually macroadenomas at the time of diagnosis, and they can grow aggressively, infiltrating surrounding tissues. Difficulty in achieving complete tumor removal at surgery can lead toward a strong tendency for recurrence, making it necessary to consider a means of treatment other than those currently used such as somatostatin analogs (SSAs), growth hormone (GH) receptor antagonist, surgical removal, and radiotherapy. The purpose of this paper is to describe a patient diagnosed with an aggressive, giant GH-secreting tumor refractory to medical therapy but ultimately treated with the radiolabeled somatostatin analog <jats:sup>90<\/jats:sup>Y-DOTATATE.<\/jats:p>\n<jats:p>A 26-year-old male with an invasive macroadenoma of the pituitary gland (5.6 \u00d7 2.5 \u00d7 3.6 cm) and biochemically confirmed acromegaly underwent 2 partial tumor resections: the first used the transsphenoidal approach and the second used the transcranial method. The patient received SSAs pre- and postoperatively. Because of the progression in pituitary tumor size, he underwent classic irradiation of the tumor (50 Gy). One and a half years later, the patient presented with clinically and biochemically active disease, and the tumor size was still 52 mm in diameter (height). Two neurosurgeons disqualified him from further surgical procedures. After confirming the presence of somatostatin receptors in the pituitary tumor by using <jats:sup>68<\/jats:sup>Ga-DOTATATE PET\/CT, we treated the patient 4 times with an SSA bound with <jats:sup>90<\/jats:sup>Y-DOTATATE. After this treatment, the patient attained partial biochemical remission and a reduction in the tumor mass for the first time.<\/jats:p>\n<jats:p>Treatment with an SSA bound with <jats:sup>90<\/jats:sup>Y-DOTATATE may be a promising option for some aggressive GH-secreting pituitary adenomas when other methods have failed.<\/jats:p>","DOI":"10.3171\/2015.6.jns15363","type":"journal-article","created":{"date-parts":[[2015,12,4]],"date-time":"2015-12-04T18:47:20Z","timestamp":1449254840000},"page":"346-349","source":"Crossref","is-referenced-by-count":32,"title":["Growth hormone\u2013secreting macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog 90Y-DOTATATE: case report"],"prefix":"10.3171","volume":"125","author":[{"given":"Joanna","family":"Walig\u00f3rska-Stachura","sequence":"first","affiliation":[{"name":"Departments of Endocrinology, Metabolism and Internal Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Gut","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology, Metabolism and Internal Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Sawicka-Gutaj","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology, Metabolism and Internal Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W\u0142odzimierz","family":"Liebert","sequence":"additional","affiliation":[{"name":"Neurosurgery and Neurotraumatology, Pozna\u0144 University of Medical Sciences, Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gryczy\u0144ska","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology, Metabolism and Internal Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Baszko-B\u0142aszyk","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology, Metabolism and Internal Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al Ricardo","family":"Blanco-Gangoo","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology, Metabolism and Internal Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Rucha\u0142a","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology, Metabolism and Internal Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"key":"b1-jns15363","series-title":"Eur J Nucl Med Mol Imaging","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","author":"Bodei","year":"2013"},{"key":"b2-jns15363","series-title":"Endokrynol Pol","first-page":"326","article-title":"Acromegaly\u2014a novel view of the patient. Polish proposals for diagnostic and therapeutic procedures in the light of recent reports","volume":"65","author":"Bolanowski","year":"2014"},{"key":"b3-jns15363","series-title":"Eur J Endocrinol","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1530\/EJE-08-0910","article-title":"Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study","volume":"161","author":"Buchfelder","year":"2009"},{"key":"b4-jns15363","series-title":"Nat Rev Endocrinol","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nrendo.2014.21","article-title":"Expert consensus document: A consensus on the medical treatment of acromegaly","volume":"10","author":"Giustina","year":"2014"},{"key":"b5-jns15363","series-title":"PLoS One","doi-asserted-by":"publisher","first-page":"e36411","DOI":"10.1371\/journal.pone.0036411","article-title":"Meta-analysis on the effects of octreotide on tumor mass in acromegaly","volume":"7","author":"Giustina","year":"2012"},{"key":"b6-jns15363","series-title":"Endocrine","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12020-014-0393-9","article-title":"ACROSTUDY: the Italian experience","volume":"48","author":"Grottoli","year":"2015"},{"key":"b7-jns15363","series-title":"Endocr Abstracts","first-page":"OC8.5","article-title":"Inoperable pituitary tumours treated with 90Y-DOTA-TATE - initial results","volume":"14","author":"Kaminski","year":"2007"},{"key":"b8-jns15363","series-title":"Tumour Biol","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s13277-012-0373-8","article-title":"The role of nuclear medicine in modern therapy of cancer","volume":"33","author":"Kramer-Marek","year":"2012"},{"key":"b9-jns15363","series-title":"Eur J Nucl Med Mol Imaging","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1007\/s00259-011-1833-x","article-title":"Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y\/177Lu-DOTATATE: which is a better therapy option?","volume":"38","author":"Kunikowska","year":"2011"},{"key":"b10-jns15363","series-title":"Tumour Biol","doi-asserted-by":"publisher","first-page":"8369","DOI":"10.1007\/s13277-014-2102-y","article-title":"PET\/CT assessment of neuroendocrine tumors of the lung with special emphasis on bronchial carcinoids","volume":"35","author":"Lococo","year":"2014"},{"key":"b11-jns15363","series-title":"Pituitary","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s11102-012-0420-x","article-title":"A consensus on the diagnosis and treatment of acromegaly complications","volume":"16","author":"Melmed","year":"2013"},{"key":"b12-jns15363","series-title":"Pituitary","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11102-010-0232-9","article-title":"Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly","volume":"15","author":"Morin","year":"2012"},{"key":"b13-jns15363","series-title":"Annales d'endocrinologie","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ando.2012.05.001","article-title":"The Liege Acromegaly Survey (LAS): A new software tool for the study of acromegaly","volume":"73","author":"Petrossians","year":"2012"},{"key":"b14-jns15363","series-title":"PLoS One","doi-asserted-by":"publisher","first-page":"e61523","DOI":"10.1371\/journal.pone.0061523","article-title":"Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis","volume":"8","author":"Pita-Gutierrez","year":"2013"},{"key":"b15-jns15363","series-title":"Neuroendocrinology","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1159\/000348394","article-title":"Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors","volume":"97","author":"Sansovini","year":"2013"},{"key":"b16-jns15363","series-title":"Endokrynol Pol","first-page":"392","article-title":"Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours","volume":"62","author":"Sowa-Staszczak","year":"2011"},{"key":"b17-jns15363","series-title":"Contemp Oncol (Pozn)","first-page":"137","article-title":"Pharmacoeconomic aspects of the treatment of pituitary gland tumours","volume":"17","author":"Sowi\u0144ski","year":"2013"},{"key":"b18-jns15363","series-title":"Neuroendocrinology","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1159\/000335018","article-title":"Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy","volume":"97","author":"van Vliet","year":"2013"}],"container-title":["Journal of Neurosurgery"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/125\/2\/article-p346.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/125\/2\/article-p346.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/125\/2\/article-p346.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,30]],"date-time":"2023-04-30T00:06:07Z","timestamp":1682813167000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/125\/2\/article-p346.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":18,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3171\/2015.6.jns15363","relation":{},"ISSN":["0022-3085","1933-0693"],"issn-type":[{"value":"0022-3085","type":"print"},{"value":"1933-0693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}